XST-20

XST-20 is an experimental small molecule inhibitor specifically designed to target **Forkhead box protein M1 (FOXM1)**, a transcription factor that acts as a potent oncogene in various malignancies, particularly ovarian cancer. Identified through structure-based in silico screening, XST-20 directly interacts with the FOXM1 **DNA-binding domain (DBD)** with a surface plasmon resonance (SPR) dissociation constant (Kd) of approximately 20 μM. By binding to this domain, the compound effectively disrupts FOXM1's ability to bind to its target DNA sequences, thereby suppressing its transcriptional activity. In preclinical models of ovarian cancer, XST-20 has demonstrated the ability to inhibit cell proliferation, reduce colony-forming efficiency, induce cell cycle arrest, and trigger apoptosis. While it is currently utilized as a research tool in preclinical studies and is available through chemical suppliers, no specific pharmaceutical developer has been identified for clinical transition.

Other names

CAS 723248-86-0CAS723248-86-0CAS-723248-86-0